OncoMatch/Clinical Trials/NCT05029063
Primary Thromboprophylaxis in Patients With Malignancy and Central Venous Catheters
Is NCT05029063 recruiting? Yes, currently enrolling (Jun 2026). This Phase 3 trial studies Rivaroxaban 10 MG for venous thromboembolism.
Treatment: Rivaroxaban 10 MG — The purpose of the full trial is to determine the efficacy and safety of prophylactic dose rivaroxaban to prevent VTE among cancer patients with CVC.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Lab requirements
Blood counts
No known thrombocytopenia (platelet count < 50x 10^9/L) in the previous 3 months
Kidney function
No severe renal insufficiency (Creatinine clearance <30 mL/min (defined by Cockcroft-Gault) in the previous 3 months)
Liver function
No documented severe liver disease (e.g., acute clinical hepatitis, chronic active hepatitis or cirrhosis) in the previous 3 months
Severe renal insufficiency (Creatinine clearance <30 mL/min (defined by Cockcroft-Gault) in the previous 3 months); Documented severe liver disease (e.g., acute clinical hepatitis, chronic active hepatitis or cirrhosis) in the previous 3 months; Known thrombocytopenia (platelet count < 50x 10^9/L) in the previous 3 months
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT05029063 currently recruiting?
Yes, this trial is currently recruiting patients.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify